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Analysis of cytoplasmic extracts of multidrug-resistant murine and hamster cells by SDS gel and 2D gel 
electrophoresis showed that they expressed an abundant 22 kDa protein which was absent from the drug 
sensitive parent lines. SDS gel electrophoresis n the presence of EGTA and direct binding tests with 45Ca2+ 
showed that the resistance-associated protein is a specific calcium-binding protein. Thus the development 
of multidrug resistance in both coic~cine-blats hamster cells and ad~amycin-sel~ted murine cells is asso- 
ciated with a major change in calcium metabolism. These observations provide the first molecular basis for 
the hypothesis that Ca2+ plays a central role in the development of the multidrug resistance phenomenon. 
Multidrug resistance Cytoplasmic protein Calcium-binding protein 
Drug eflux 
CP,, protein Calcium antagonist 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Somatic mammalian cells selected for resistance 
to one type of cytotoxic drug frequently develop 
resistance to drugs of unrelated structure and func- 
tion [1,2]. The mechanisms underlying this 
multidrug resistance (MDR) phenomenon are 
unknown, but evidence exists that both decreased 
drug penetration [3-51 and increased drug efflux 
16-191 occur in resistant cells. Decreased drug 
penetration appears to result from membrane 
changes due to increased expression of a plasma 
membrane glycoprotein (P-glycoprotein) [20,2 11. 
Increased drug efflux appears to result from a 
Ca’+-dependent process, since it is inhibited by 
calcium antagonists 116-191. However, little is 
known about the molecular basis of this latter pro- 
cess. Here, it is shown for the first time that MDR 
cells express a novel major calcium-binding protein 
which could provide the molecular basis for the 
calcium-dependent increase in drug efflux in 
m~tidrug-resistant cells. 
2.1. Cells 
CHO-AUX and CHO-CS cells [24] were kindly 
provided by Dr V. Ling. EMT6 AR1 (table 1) is a 
Table 1 
Drug sensitivity of EMT6/Ca/VJAC cells 
Drug JDso CuJmB 
EMT6 EMT6-AR1 
Adriamycin 0.020 0.60 
Vincristine 0.013 0.62 
Colchicine 0.0055 0.38 
EMT6/Ca/VJAC [29] cells were grown in increasing 
amounts of adriamycin over 8 weeks until they became 
resistant to 1 .O pg/ml adriamycin (EMT6-ARI). 
Multidrug resistance was determined by measuring the 
IDsa @g/ml) of drug required to inhibit cell growth by 
50%. 5 x 104 cells were initiated at day 0 in the presence 
of the drug and allowed to grow for 3 days (parent line) 
or 4 days (resistant line) at which stage control samples 
contained 2 x IO6 and 1 x lo6 cells, respectively 
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multidrug-resistant derivative of the murine EMT6 
line [25]. 
2.2. Preparation of ceil extracts 
through an 18 gauge needle. Cell debris was spun 
out 30000 x g and the supernatant used as a 
cytoplasmic extract. 
Celb were suspended in 10 mM Tris-HCI (pH 
7.5) on ice for 30 min and lysed by syringing 
2.3. Gel e~ectr~ph~res~s 
SDS-polyacrylamide gel electrophoresis was car- 
r* 
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Fig. 1. An abundant cytosofic protein in multidrug resistant hamster and mouse cells, (A,B) SDS-polyacrylamide gefs 
of cell extracts from sensitive and resistant ceils. (A) Gel stained with PAGE blue 83. (B) Low-mo~~ular-mass section 
of the same gel as A stained with the silver stain [29]. Small arrowheads show standard markers [(a) glycogen 
phosphorylase, 95 kDa; (b) bovine serum albumin, 65 kDa; (c) ovalbumin, 45 kDa; (d) carbonic anhydrase, 30 kDa; 
(e) cY-lactalbumin, 15 kDa]. The large arrowheads how the 22 kDa protein. (1) CHO-AUX, (2) CMO-CS, (3) EMT6, 
(4) EMT6ARl . (C) 20 polyacrylamide gels (281 of extracts from sensitive and resistant cells. (1) CHO-AUX, (2) CHO- 
CS, (3) EMT&ARl. The arrow points to actin and the large arrowhead to the position of the 22 kDa protein (~15.3). 
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ried out according to Laemmli [26] and Mat- 
sudaira and Burgess [27]. 2D gel electrophoresis 
was as described by O’Farrell [28]. Silver staining 
was as described by Wray et al. [29]. 
2 4. Calcium binding 
This was exactly as described by Maruyama et 
al. [23] using 4’CaC12 from Amersham. 
1 2 
A +- 
3. RESULTS 
SDS-polyacrylamide gel electrophoresis of ex- 
tracts of the soluble proteins from the multidrug- 
resistant CHO-CS and EMTdARI cells showed 
that they hyper-expressed a major 22 kDa protein, 
compared with the parent cell lines AUX and 
EMT6, respectively (fig.1). 2D gel analysis re- 
vealed that the murine and hamster proteins 
mapped at the same position (~15.3) showing that 
they are the same. Thus, resistance in both these 
murine and hamster cells selected with either col- 
chicine or adriamycin is associated with hyper- 
expression of the same 22 kDA protein. 
Two lines of evidence showed that the 22 kDa 
protein is a calcium-binding protein. SDS gel elec- 
trophoresis in the presence of EGTA [22] (fig.2) 
caused a small but significant decrease in the 
mobility of the 22 kDa protein. The shift which oc- 
curs is less than that obtained with calmodulin 
which has 4 calcium-binding sites but is com- 
parable to that of myosin light chain 2 which has 
only one. Confirmation of the calcium-binding 
capacity of the protein was obtained from a direct 
assay with 45Ca2+ on nitrocellulose paper [23]. The 
22 kDa protein was one of the major calcium- 
binding proteins in the extracts. No comparable 
activity was evident in the parent AUX line, con- 
firming that binding was to the resistance- 
associated protein. When the concentration of 
45CaC12 was varied from 1 x 1O-5 to 1 x lo-’ M 
in the nitrocellulose binding assay, half-maximal 
binding occurred at 2 x 10e6 M. When the binding 
- 
Fig.2. Binding of Ca’+ to the 22 kDa protein in 
multidrug-resistant cells. (A) Analysis for calcium- 
binding proteins by SDS-polyacrylamide gel electro- 
phoresis. Samples were run on mini-gradient gels 
(JO-20% polyacrylamide) [27] in the presence (+ ) and 
absence (- ) of 1 mM EGTA [22]. (1) CHO-CS cell 
extract (see fig.1); (2) CHO-CS extracts as in (1); (+) 
and ( - ) tracks were split after photography and aligned 
for maximum coincidence by eye, (3) bovine brain 
calmodulin; (4) rabbit muscle myosin (arrow shows 
myosin LC2, the main calcium-binding protein). The 
arrowheads show the position of the 22 kDa protein in 
CHO-C5 cells. (1) CHO-AUX, (2) CHO-CS. (A) 
Autoradiograph, (P) protein. Contrast in the protein 
stain is poor because the amido black stain was used. 
PAGE blue 83 is incompatible with nitrocellulose. The 
arrow shows the position of the 22 kDa protein. 
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was carried out in the presence of MgClz from 1 x 
10m6 to 1 x IO-’ M, half-maximal inhibition oc- 
curred at 10 mM MgCI2. Thus the protein has a 
strong and specific affinity for Ca2+. 
4. DISCUSSION 
This is the first demonstration that rnultidrug- 
resistant cells hyper-express acalcium-binding pro- 
tein (CP22). Although only 2 MDR cells were ex- 
amined here, the expression of a similar protein 
(22 kDa, ~15.3) has been reported in several other 
MDR lines [30,31]. Thus hyper-expression of the 
CP22 protein appears to be a common correlate of 
the MDR phenomenon, at least in rodent cells. 
Two features of the CPZZ protein are particularly 
significant in relation to multidrug resistance. 
First, the protein is easily the major change in pro- 
tein composition in such cells and is therefore a 
major candidate product of the gene amplification 
events which accompany multidrug resistance [32]. 
It is noteworthy that this is also the first qeport that 
the CHO-C5 cell, which is the prototype line [20] 
for .the study of P-glycoprotein expression in 
multidrug-resistant cells, also expresses the CP22 
protein. Thus P-glycoprotein expression is not the 
only, or even the major compositions change oc- 
curring in these cells. The second significant point 
stems from the presence of such a major calcium- 
binding protein in the cytoplasm of the resistant 
cells. The specificity and affinity of the CPZZ pro- 
tein for calcium are comparable to that of proteins 
such as calmodulin and clearly implies that the 
protein has the ability to bind calcium in the cell. 
The remarkable feature of CP22 is the fact that its 
intracellular concentration is estimated at approx. 
1OOpM in the resistant cells. Thus by its very 
presence CPZZ would subst~ti~ly alter calcium 
metabolism in the cell since its level far exceeds the 
level of free calcium (approx. 1 x lo-’ M) and it 
could bind as much as 10% of the total cellular 
calcium. We therefore conclude that calcium 
metabolism is significantly different in the 
multidrug-resistant cells compared with the sen- 
sitive parents. Since CP22 expression is a common 
correlate of the development of multidrug 
resistance (see above), it implies that such changes 
in calcium metabolism are necessary, but perhaps 
not sufficient, for the development of the 
multi~ug resistance phenotype. 
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The implication of changes in calcium 
metabolism in multidrug resistance is not unex- 
pected. Studies with calcium antagonists such as 
the drug verapamil have shown that these agents 
reduce the efflux of drugs and reverse the 
resistance in MDR cells [10,19], indicating that 
Ca2+ is important in the drug efflux mechanism. 
Analysis of this phenomenon, which is of not in- 
considerable clinical significance, has been dif- 
ficult because the mechanism of drug efflux is 
unknown. The fact that CPz2 is a calcium-binding 
protein provides independent evidence for the in- 
volvement of Ca2+ in the efflux mechanism, but 
more importantly, provides a biochemical handle 
for the examination of the drug efflux m~h~ism. 
In summary, these studies have shown that the 
development of multidrug resistance in murine and 
hamster cells is accompanied by the expression of 
an abundant calcium-binding protein and thereby 
provides a molecular basis for the changes in 
calcium-de~ndent drug efflux which accompanies 
development of the resistant phenotype. 
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